Featured today in this post is Dr Krisztina Nemenyi, Group Director-Asia Pacific, Global Regulatory Sciences-International, Bristol-Myers Squibb Co., Republic Of Korea. She will be speaking at Pharma Trials World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
A short introduction: Dr Krisztina is presently Group Director of Regulatory Affairs for Asia-Pacific Region with responsibilities for Australia, Hong Kong, Korea, Singapore, Taiwan, and Thailand at Bristol Myers Squibb Company (BMS). She is responsible for partnering effectively with the commercial and medical organizations and the GRS International Strategy Leads to develop and execute successful regulatory strategies for all products in these markets. She is also responsible for defining and driving local regulatory processes and registration strategy to ensure timely market access of new products and line extensions. Previously, Dr Krisztina was Director of Regulatory Affairs for Oncology Therapeutic Area at BMS overseeing the development of various oncology compounds in different stages of development. Krisztina received her Ph.D. degree from the Technical University of Vienna, Austria in the field of chemical engineering. She has been in the regulatory affairs field for more than ten years and with BMS for five years.
Dr Krisztina will be participating in the following panel:
Regulatory panel: Overcoming regulatory barriers in Asia to fast-track clinical trials
1. Identifying crucial compliance areas in Asian regulations for accelerated drug approval
2. Mapping the direction of regulatory affairs for Asia in the next five years and identifying areas of improvements
3. Developing a platform to enhance two-way communications between regulators and industry for improved regulatory compliance